TY - JOUR
T1 - Randomized controlled trial of tamsulosin for prevention of acute voiding difficulty after rectal cancer surgery
AU - Jang, Je Ho
AU - Kang, Sung Bum
AU - Lee, Sung Min
AU - Park, Jun Seok
AU - Kim, Duck Woo
AU - Ahn, Soyeon
PY - 2012/11
Y1 - 2012/11
N2 - Background: We conducted a randomized clinical trial to investigate the efficacy of the selective a1A-adrenoceptor antagonist tamsulosin in preventing acute voiding difficulty after rectal cancer surgery. Methods: A total of 94 rectal cancer patients with an International Prostate Symptom Score (IPSS) of ≤7 were randomly assigned (1:1) to the tamsulosin group (0.2 mg/day orally for 7 days) (n = 47) or the control group (n = 47). The primary endpoint was the reinsertion rate of the urinary catheter after its removal on postoperative day (POD) 3. The secondary endpoints included the maximum (Qmax) and average (Qavg) urinary flow rates on POD 3, and the voided volume (VV), residual urine volume (RU), and IPSS on POD 7. Analyses were based on an intention-to-treat population. Results: The reinsertion rate of the urinary catheter in the tamsulosin group was similar to that in the control group (23.4 vs. 21.3 %, respectively; p = 0.804). The postoperative voiding parameters and IPSS were not better in the tamsulosin group than in the control group after adjustments were made for the baseline measurements with analysis of covariance (Qmax, p = 0.537; Qavg, p = 0.399; VV, p = 0.645; RU, p = 0.703; IPSS, p = 0.761). Multivariate analysis revealed that being male was the only independent risk factor for reinsertion of the urinary catheter (odds ratio 0.239; 95 % confidence interval 0.069-0.823; p = 0.023). Conclusions: This controlled trial showed that tamsulosin at 0.2 mg/day does not prevent acute voiding difficulty after rectal cancer surgery.
AB - Background: We conducted a randomized clinical trial to investigate the efficacy of the selective a1A-adrenoceptor antagonist tamsulosin in preventing acute voiding difficulty after rectal cancer surgery. Methods: A total of 94 rectal cancer patients with an International Prostate Symptom Score (IPSS) of ≤7 were randomly assigned (1:1) to the tamsulosin group (0.2 mg/day orally for 7 days) (n = 47) or the control group (n = 47). The primary endpoint was the reinsertion rate of the urinary catheter after its removal on postoperative day (POD) 3. The secondary endpoints included the maximum (Qmax) and average (Qavg) urinary flow rates on POD 3, and the voided volume (VV), residual urine volume (RU), and IPSS on POD 7. Analyses were based on an intention-to-treat population. Results: The reinsertion rate of the urinary catheter in the tamsulosin group was similar to that in the control group (23.4 vs. 21.3 %, respectively; p = 0.804). The postoperative voiding parameters and IPSS were not better in the tamsulosin group than in the control group after adjustments were made for the baseline measurements with analysis of covariance (Qmax, p = 0.537; Qavg, p = 0.399; VV, p = 0.645; RU, p = 0.703; IPSS, p = 0.761). Multivariate analysis revealed that being male was the only independent risk factor for reinsertion of the urinary catheter (odds ratio 0.239; 95 % confidence interval 0.069-0.823; p = 0.023). Conclusions: This controlled trial showed that tamsulosin at 0.2 mg/day does not prevent acute voiding difficulty after rectal cancer surgery.
UR - http://www.scopus.com/inward/record.url?scp=84867854835&partnerID=8YFLogxK
U2 - 10.1007/s00268-012-1712-z
DO - 10.1007/s00268-012-1712-z
M3 - Article
C2 - 22806208
AN - SCOPUS:84867854835
SN - 0364-2313
VL - 36
SP - 2730
EP - 2737
JO - World Journal of Surgery
JF - World Journal of Surgery
IS - 11
ER -